Inhibition of FLT3 in AML: a focus on sorafenib.

about

The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.The importance of FLT3 mutational analysis in acute myeloid leukemia.

P2860

Q47229822-C0E9351B-39E6-4268-9DCB-298BBA7FE584 Q48255430-3F8D7C06-83C7-4608-8E0A-10E1979891AF

P2860

Inhibition of FLT3 in AML: a focus on sorafenib.

Item

http://www.wikidata.org/entity/Q38989349

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Inhibition of FLT3 in AML: a focus on sorafenib.

@en

type

Item

label

Inhibition of FLT3 in AML: a focus on sorafenib.

@en

prefLabel

Inhibition of FLT3 in AML: a focus on sorafenib.

@en

P1476

Inhibition of FLT3 in AML: a focus on sorafenib.

@en

P2093

A Antar

http://www.w3.org/2001/XMLSchema#string

G Battipaglia

http://www.w3.org/2001/XMLSchema#string

J El-Cheikh

http://www.w3.org/2001/XMLSchema#string

M A Kharfan-Dabaja

http://www.w3.org/2001/XMLSchema#string

M Mohty

http://www.w3.org/2001/XMLSchema#string

R Mahfouz

http://www.w3.org/2001/XMLSchema#string

Z K Otrock

http://www.w3.org/2001/XMLSchema#string

P2860

The role of FLT3 in haematopoietic malignancies

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

P2888

bmt.2016.251

P304

344-351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2016.251

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ali Bazarbachi

P577

2016-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043106990

http://www.w3.org/2001/XMLSchema#string

P698

27775694

http://www.w3.org/2001/XMLSchema#string

Inhibition of FLT3 in AML: a focus on sorafenib.

about

P2860

P2860

Inhibition of FLT3 in AML: a focus on sorafenib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698